The current results are consistent with the online database data: strong FTH1 (Fig. 1c) but not FTL (Fig. 1d) expression is significantly correlated with worsened survival of patients with pancreatic cancer as well as in those with high FTH1–KRAS co-occurrence (Supplementary Fig. 6b). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.